FIDURA Private Equity Funds: Successful sale of portfolio company m2p-labs GmbH to Beckman Coulter Life Sciences

Grünwald, 13.11.2020 (lifePR) – FIDURA Private Equity Funds, headquartered in Gruenwald near Munich, Germany and co-investors including the High-Tech Gründerfonds, the KfW, the Gesellschaft für innovative Beteiligungen Aachen and others, have sold their complete stake in m2p-labs GmbH to Beckman Coulter Life Sciences
Founded in 2005, m2p-labs is a leading global manufacturer of microbioreactors.
„m2p“ stands for „from microreactor to process“.
Using optical measuring technology and microfluidic chip technology combined with miniaturization and intelligent analyses methods, the company created an innovative system (BioLector®Technology) that provides the user with important information in a non-invasive way and with online monitoring during the process already at a very early stage of development in microscale. The user is thus able to efficiently develop a multitude of bioprocesses and products in a much shorter time to market.
The technology is suitable for diverse screening tasks such as strain selection, promoter characterization, optimization of culture media and bioprocess development.
“Innovation defines our future,” said Greg Milosevich, President, Beckman Coulter Life Sciences. “m2p-labs core product line complements our existing liquid handling and laboratory automation business. It provides new opportunities for our collective team to develop and enhance time-saving solutions for cell line development and process development workflows.”
We are pleased to have found in Beckman Coulter Life Sciences the ideal strategic partner to further realize the great potential of the m2p product portfolio. Our buy-and-build strategy has thus been implemented extremely successfully, adds Klaus Ragotzky, Managing Director of lead investor FIDURA Private Equity Fonds.
Marco Winzer, Partner of High-Tech Gründerfonds and Dr. Christoph Petry, CEO of m2p-labs GmbH, add: „Our consortium of investors was for many years an excellent financial partner and sparring partner for the m2p team. This helped enable the company to realise rapid growth as a market leader in bioprocessing and develop unique microfluidic technology while optimizing and improving internal processes.“
About Beckman Coulter Life Sciences
Beckman Coulter Life Sciences develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. For more than 75 years, the products of Beckman Coulter have been making a difference in people’s lives by improving the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery.
For more information visit www.beckman.com

Unternehmen: FIDURA Private Equity Fonds